Limited sampling strategies for therapeutic drug monitoring of linezolid in patients with multidrug-resistant tuberculosis

Therapeutic Drug Monitoring

Volumn 32, Issue 1, 2010, Pages 97-101

  Alffenaar, Jan Willem C ^a   Kosterink, Jos G W ^a   Van Altena, Richard ^a   Van Der Werf, Tjip S ^a   Uges, Donald R A ^a   Proost, Johannes H ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Limited sampling; Linezolid; MDR TB; Pharmacokinetics; Therapeutic drug monitoring

Indexed keywords

LINEZOLID;

AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG MONITORING; HUMAN; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANT TUBERCULOSIS; PRIORITY JOURNAL; TIME TO MAXIMUM PLASMA CONCENTRATION;

ACETAMIDES; ADULT; ANTI-INFECTIVE AGENTS; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG MONITORING; HUMANS; OXAZOLIDINONES; PROSPECTIVE STUDIES; TANDEM MASS SPECTROMETRY; TUBERCULOSIS, MULTIDRUG-RESISTANT; YOUNG ADULT;

EID: 75649136552     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3181cc6d6f     Document Type: Article

References (35)

1. Maartens G, Wilkinson RJ. Tuberculosis. Lancet 2007;370:2030-2043.
2. Raviglione MC, Smith IM. XDR tuberculosis-implications for global public health. N Engl J Med. 2007;356:656-659.
3. World Health Organization. Global Tuberculosis Control: Surveillance, Planning, Financing: Goals, Targets and Indicators for TB Control. Report WHO/HTM/TB/2008.393. 2008.
4. World Health Organization. Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis. WHO/HTM/TB/2006.361, 1-185. Geneva: WHO; 2006.
5. Geerligs WA, van Altena R, De Lange WCM, et al. Multidrug-resistant tuberculosis: long-term treatment outcome in the Netherlands. Int J Tuberc Lung Dis. 2000;4:758-764.
6. Turett, GS, Telzak EE, Torian LV, et al. Improved outcomes for patients with multidrug-resistant tuberculosis. Clin Infect Dis. 1995;21: 1238-1244.
7. Salomon N, Perlman DC, Friedmann P, et al. Predictors and outcome of multidrug-resistant tuberculosis. Clin Infect Dis. 1995;21:1245-1252.
8. Cohn DL. Treatment of multidrug-resistant tuberculosis. J Hosp Infect. 1995;30(Suppl):322-328.
9. Brickner SJ, Hutchinson DK, Barbachyn MR, et al. Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant Gram-positive bacterial infections. J Med Chem. 1996;39:673-679.
10. Rodriguez JC, Ruiz M, Lopez M, et al. In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis. Int J Antimicrob Agents 2002;20:464-467.
11. Fortun J, Martin-Davila P, Navas E, et al. Linezolid for the treatment of multidrug-resistant tuberculosis. J Antimicrob Chemother. 2005;56: 180-185.
12. Slebos DJ, van Altena R. Linezolid, an agent from a new class of antibiotics [in Dutch]. Ned Tijdschr Geneeskd. 2004;148:2462-2463.
13. Condos R, Hadgiangelis N, Leibert E, et al. Case series report of a linezolid-containing regimen for extensively drug-resistant tuberculosis. Chest. 2008;134:187-192.
14. Yew WW, Chau CH, Wen KH. Linezolid in the treatment of 'difficult' multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2008;12: 345-346.
15. von der Lippe B, Sandven P, Brubakk O. Efficacy and safety of linezolid in multidrug resistant tuberculosis (MDR-TB)-a report of ten cases. J Infect. 2006;52:92-96.
16. Bishop E, Melvani S, Howden BP, et al. Good Clinical outcomes but high rates of adverse reactions during linezolid therapy for serious infections: a proposed protocol for monitoring therapy in complex patients. Antimicrob Agents Chemother. 2006;50:1599-1602.
17. Bressler AM, Zimmer SM, Gilmore JL, et al. Peripheral neuropathy associated with prolonged use of linezolid. Lancet Infect Dis. 2004;4: 528-531.
18. French G. Safety and tolerability of linezolid. J Antimicrob Chemother. 2003;51(Suppl 2):ii45-ii53.
19. Eker B, Ortmann J, Migliori GB, et al. Multidrug-and extensively drug-resistant tuberculosis, Germany. Emerg Infect Dis. 2008;14:1700-1706.
20. Andes D, van Ogtrop ML, Peng J, et al. In vivo pharmacodynamics of a new oxazolidinone (linezolid). Antimicrob Agents Chemother. 2002;46: 3484-3489.
21. Boak LM, Li J, Rayner CR, et al. Pharmacokinetic/pharmacodynamic factors influencing emergence of resistance to linezolid in an in vitro model. Antimicrob Agents Chemother. 2007;51:1287-1292.
22. Craig WA. Does the dose matter? Clin Infect Dis. 2001;33(Suppl 3): S233-S237.
23. Rayner CR, Forrest A, Meagher AK, et al. Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme. Clin Pharmacokinet. 2003;42:1411-1423.
24. Rodriguez JC, Cebrian L, Lopez M, et al. Mutant prevention concentration: comparison of fluoroquinolones and linezolid with Mycobacterium tuberculosis. J Antimicrob Chemother. 2004;53:441-444.
25. 0-24h, area under the concentrate-time curve 0 to 24 hours of intractable multidrug-resistant and extensively drug-resistant tuberculosis. J Antimicrob Chemother. 2009;64:879-883
26. Pfizer. Zyvoxid. Product Information 2005.
27. Islinger F, Dehghanyar P, Sauermann R, et al. The effect of food on plasma and tissue concentrations of linezolid after multiple doses. Int J Antimicrob Agents. 2006;27:108-112.
28. Harmelink IM, Alffenaar JWC, Wessels AMA, et al. A rapid and simple liquid chromatography-tandem mass spectrometry method for the determination of linezolid in human serum. Eur J Hosp Pharm. 2008; 14:5-8.
29. Proost JH, Meijer DK. MW/Pharm, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring. Comput Biol Med. 1992;22:155-163.
30. Welshman IR, Sisson TA, Jungbluth GL, et al. Linezolid absolute bioavailability and the effect of food on oral bioavailability. Biopharm Drug Dispos. 2001;22:9197.
31. Alffenaar JWC, van Altena R, Harmelink IM, et al. Comparison of pharmacokinetics and tolerability of two dosage regime of linezolid in MDR/XDR-TB patients. Clin Pharmacokinet. In press.
32. Peloquin CA, Hadad DJ, Molino LP, et al. Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. Antimicrob Agents Chemother. 2008;52:852-857.
33. Wilkins JJ, Savic RM, Karlsson MO, et al. Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechan-istic model to describe variable absorption. Antimicrob Agents Chemother. 2008;52:2138-2148.
34. Plock N, Buerger C, Joukhadar C, et al. Does linezolid inhibit its own metabolism? Population pharmacokinetics as a tool to explain the observed nonlinearity in both healthy volunteers and septic patients. Drug Metab Dispos. 2007;35:1816-1823.
35. Dietze R, Hadad DJ, McGee B, et al. Early and extended early bactericidal activity of linezolid in pulmonary tuberculosis. Am J Respir Crit Care Med. 2008;178:1180-1185.